GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (NAS:SILK) » Definitions » Beneish M-Score

Silk Road Medical (Silk Road Medical) Beneish M-Score : -2.79 (As of May. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.79 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Silk Road Medical's Beneish M-Score or its related term are showing as below:

SILK' s Beneish M-Score Range Over the Past 10 Years
Min: -2.81   Med: -2.23   Max: -0.25
Current: -2.79

During the past 7 years, the highest Beneish M-Score of Silk Road Medical was -0.25. The lowest was -2.81. And the median was -2.23.


Silk Road Medical Beneish M-Score Historical Data

The historical data trend for Silk Road Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silk Road Medical Beneish M-Score Chart

Silk Road Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -0.25 -2.81 -2.10 -2.53 -1.84

Silk Road Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.02 -2.06 -2.54 -1.84 -2.79

Competitive Comparison of Silk Road Medical's Beneish M-Score

For the Medical Devices subindustry, Silk Road Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silk Road Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's Beneish M-Score falls into.



Silk Road Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Silk Road Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1079+0.528 * 0.9856+0.404 * 0.4297+0.892 * 1.2304+0.115 * 0.8906
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0015+4.679 * -0.07476-0.327 * 1.045
=-2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $27.2 Mil.
Revenue was 48.484 + 47.27 + 44.435 + 45.298 = $185.5 Mil.
Gross Profit was 36.501 + 34.802 + 32.385 + 32.294 = $136.0 Mil.
Total Current Assets was $235.7 Mil.
Total Assets was $252.3 Mil.
Property, Plant and Equipment(Net PPE) was $8.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.7 Mil.
Selling, General, & Admin. Expense(SGA) was $151.7 Mil.
Total Current Liabilities was $21.3 Mil.
Long-Term Debt & Capital Lease Obligation was $75.9 Mil.
Net Income was -14.136 + -13.011 + -12.788 + -13.484 = $-53.4 Mil.
Non Operating Income was 0.048 + 0.477 + -0.002 + 0.11 = $0.6 Mil.
Cash Flow from Operations was -15.322 + -8.453 + -6.798 + -4.616 = $-35.2 Mil.
Total Receivables was $20.0 Mil.
Revenue was 40.131 + 40.071 + 37.374 + 33.173 = $150.7 Mil.
Gross Profit was 27.605 + 29.092 + 28.066 + 24.161 = $108.9 Mil.
Total Current Assets was $230.3 Mil.
Total Assets was $259.6 Mil.
Property, Plant and Equipment(Net PPE) was $8.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.5 Mil.
Selling, General, & Admin. Expense(SGA) was $123.1 Mil.
Total Current Liabilities was $20.9 Mil.
Long-Term Debt & Capital Lease Obligation was $74.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(27.203 / 185.487) / (19.956 / 150.749)
=0.146657 / 0.132379
=1.1079

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(108.924 / 150.749) / (135.982 / 185.487)
=0.722552 / 0.733108
=0.9856

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (235.694 + 8.085) / 252.314) / (1 - (230.254 + 8.897) / 259.587)
=0.033827 / 0.078725
=0.4297

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=185.487 / 150.749
=1.2304

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.486 / (3.486 + 8.897)) / (3.737 / (3.737 + 8.085))
=0.281515 / 0.316106
=0.8906

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(151.724 / 185.487) / (123.125 / 150.749)
=0.817976 / 0.816755
=1.0015

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((75.886 + 21.337) / 252.314) / ((74.848 + 20.87) / 259.587)
=0.385325 / 0.368732
=1.045

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-53.419 - 0.633 - -35.189) / 252.314
=-0.07476

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Silk Road Medical has a M-score of -2.79 suggests that the company is unlikely to be a manipulator.


Silk Road Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Silk Road Medical (Silk Road Medical) Business Description

Traded in Other Exchanges
Address
1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Executives
Chas Mckhann director, officer: Chief Executive Officer 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Marie L. Jones officer: CAO and VP, Finance 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Lucas W. Buchanan officer: Chief Financial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Kevin M Klemz officer: EVP/Chief Legal Officer/Sec. 9600 54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55442
Andrew S. Davis officer: Chief Commercial Officer C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Erica J. Rogers director, officer: President and CEO C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard Ruedy officer: EVP Clin & Reg. Affairs and QA C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tony M. Chou director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tanisha Carino director C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Rick D Anderson director 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Donald Zurbay director C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Warburg Pincus Partners Gp Llc 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus & Co. 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147